Acute treatment response and its predictors in patients with first-episode psychosis in Iran

References

• Crespo-Facorro B, Pelayo-Teran JM, Perez-Iglesias R, et al. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variables. Journal of Psychiatric Research 2007; 41: 659–666
   PubMed Web of Science ®Google Scholar
• Emsley R, Oosthuizen PP, Kidd M, Koen L, Niehaus DJ, Turner HJ. Remission in first-episode psychosis: predictor variables and symptom improvement patterns. Journal of Clinical Psychiatry 2006; 67: 1707–1712
   PubMed Web of Science ®Google Scholar
• Craig TJ, Siegel C, Hopper K, Lin S, Sartorius N. Outcome in schizophrenia and related disorders compared between developing and developed countries. A recursive partitioning re-analysis of the WHO DOSMD data. British Journal of Psychiatry 1997; 170: 229–233
   PubMed Web of Science ®Google Scholar
• Alaghband-Rad J, Boroumand M, Amini H, et al. Non-affective acute remitting psychosis: a preliminary report from Iran. Acta Psychiatrica Scandinavica 2006; 113: 96–101
   PubMed Web of Science ®Google Scholar
• Sartorius N, Jablensky A, Shapiro R. Two-year follow-up of the patients included in the WHO International Pilot Study of Schizophrenia. Psychological Medicine 1977; 7: 529–541
   PubMed Web of Science ®Google Scholar
• Amini H, Alaghband-Rad J, Omid A, et al. Diagnostic stability in patients with first-episode psychosis. Australasian Psychiatry 2005; 13: 388–392
   PubMedGoogle Scholar
• Jablensky A, Sartorius N, Ernberg G, et al. Schizophrenia: manifestations, incidence and course in different culture. A World Health Organization ten-country study. Psychological Medicine Monograph 1992; 20(Suppl.)1–97
   Google Scholar
• Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 2003; 64: 663–667
   PubMed Web of Science ®Google Scholar
• Szekeres G, Keri S, Juhasz A, et al. Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. American Journal of Medical Genetics B Neuropsychiatric Genetics 2004; 124: 1–5
   Google Scholar
• Goff DC, Tsai G, Levitt J, et al. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Archives of General Psychiatry 1999; 56: 21–27
   PubMed Web of Science ®Google Scholar
• Norman RM, Malla AK, Cortese L, Diaz F. A study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS. Schizophrenia Research 1996; 19: 73–85
   PubMed Web of Science ®Google Scholar
• Robinson DG, Woerner MG, Delman HM, Kane JM. Pharmacological treatments for first-episode schizophrenia. Schizophrenia Bulletin 2005; 31: 705–722
   PubMed Web of Science ®Google Scholar
• Hopper K, Wanderling J. Revisiting the developed versus developing country distinction in course and outcome in schizophrenia: results from ISoS, the WHO collaborative followup project. International Study of Schizophrenia. Schizophrenia Bulletin 2000; 26: 835–846
   PubMed Web of Science ®Google Scholar
• Penn DL, Waldheter EJ, Perkins DO, Mueser KT, Lieberman JA. Psychosocial treatment for first-episode psychosis: a research update. American Journal of Psychiatry 2005; 162: 2220–2232
   PubMed Web of Science ®Google Scholar
• Lehtinen V, Aaltonen J, Koffert T, Räkköläinen V, Syvälahti E. Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed?. European Psychiatry 2000; 15: 312–320
   PubMed Web of Science ®Google Scholar
• Conus P, Cotton S, Abdel-Baki A, Lambert M, Berk M, McGorry PD. Symptomatic and functional outcome 12 months after a first episode of psychotic mania: barriers to recovery in a catchment area sample. Bipolar Disorders 2006; 8: 221–231
   PubMed Web of Science ®Google Scholar
• Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 2004; 161: 473–479
   PubMed Web of Science ®Google Scholar
• Hatta K, Nakamura H, Matsuzaki I. Acute-phase treatment in general hospitals: clinical psychopharmacologic evaluation in first-episode schizophrenia patients. General Hospital Psychiatry 2003; 25: 39–45
   PubMed Web of Science ®Google Scholar
• Perkins D, Lieberman J, Gu H, et al. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. British Journal of Psychiatry 2004; 185: 18–24
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Harvey PD, Eerdekens M, Davidson M. Premorbid functioning and treatment response in recent-onset schizophrenia. British Journal of Psychiatry 2006; 189: 31–35
   PubMed Web of Science ®Google Scholar
• Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 1999; 156: 544–549
   PubMed Web of Science ®Google Scholar
• Mojtabai R, Susser ES, Bromet EJ. Clinical characteristics, 4-year course, and DSM-IV classification of patients with nonaffective acute remitting psychosis. American Journal of Psychiatry 2003; 160: 2108–15
   PubMed Web of Science ®Google Scholar
• Susser E, Varma VK, Mattoo SK, et al. Long-term course of acute brief psychosis in a developing country setting. British Journal of Psychiatry 1998; 173: 226–230
   PubMed Web of Science ®Google Scholar
• Susser E, Wanderling J. Epidemiology of nonaffective acute remitting psychosis vs schizophrenia. Sex and sociocultural setting. Archives of General Psychiatry 1994; 51: 294–301
   PubMed Web of Science ®Google Scholar